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Abstract
Studies on trafficking of endogenous opioid receptors in vivo are subject of the present review.
In many of the in vivo studies, the use of semi-quantitative immuno-electron microscopy is the
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approach of choice. Endogenous opioid receptors display differential subcellular distributions
with µ opioid receptor (MOPR) being mostly present on the plasma membrane and δ- and κopioid receptors (DOPR and KOPR, respectively) having a significant intracellular pool.
Etorphine and DAMGO cause endocytosis of the MOPR, but morphine does not, except in some
dendrites. Interestingly, chronic inflammatory pain and morphine treatment promote trafficking
of intracellular DOPR to the cell surface which may account for the enhanced antinociceptive
effects of DOPR agonists. KOPR has been reported to be associated with secretory vesicles in
the posterior pituitary and translocated to the cell surface upon salt loading along with the release
of vasopressin. The study of endogenous opioid receptors using in vivo models has produced
some interesting results that could not have been anticipated in vitro. In vivo studies, therefore,
are essential to provide insight into the mechanisms underlying opioid receptor regulation.
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Introduction
Opioid receptors belong to the seven-transmembrane receptor superfamily and are coupled with
Gi/o proteins. Three types of opioid receptors have been cloned, µ- , δ- and κ-opioid receptor
(MOPR, DOPR and KOPR, respectively).
Opioid receptors can be activated by a variety of naturally occurring or synthetic opiates and
several endogenous neuropeptides. When the opioid receptors are activated upon binding of
these ligands, a common regulatory event involves internalization of the receptor from the cell
surface to intracellular sites. Agonist-induced endocytosis of opioid receptors has been studied
extensively in cell models. Briefly, following binding of agonists to opioid receptors on plasma
membranes, receptors undergo conformational changes leading to activation of G proteins and
translocation of G protein-coupled receptor kinases to the cell surface resulting in
phosphorylation of the receptors. β-arrestins are recruited to the phosphorylated receptors, which
are subsequently endocytosed via a clathrin-dependent pathway. The decrease in the numbers of
cell surface opioid receptors may be an adaptive process to avoid over-stimulation and may
account in part for tolerance to opioids. Internalized opioid receptors are either recycled back to
cell surface, resulting in re-sensitization of the receptors or sorted to degradation pathways,
leading to down-regulation (Liu-Chen, 2004; von Zastrow et al., 2003).
Like endocytosis, trafficking of opioid receptors to the cell surface may also be regulated. In
dissociated dorsal root ganglion neurons, DOPR is sorted into large dense-core vesicles through
interaction with protachykinin (Guan et al., 2005). Activation of surface DOPR causes elevation
of intracellular Ca2+ mostly via an inositol triphosphate-dependent mechanism that results in
insertion of large dense-core vesicles-associated DOPR onto the cell surface (Bao et al., 2003).
Another mechanism leading to an increase of opioid receptors on the cell surface is the
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pharmacological chaperone effects of opioid ligands. In cells transfected with opioid receptors,
cell-permeant opioid ligands promote endoplasmic reticulum-to-Golgi trafficking of opioid
receptors to enhance cell surface expression by facilitating correct folding of the newly
synthesized receptors at the endoplasmic reticulum (Chen et al., 2006; Petaja-Repo et al., 2002;
Wannemacher et al., 2007; Chaipatikul et al., 2003).
Most studies on opioid receptor trafficking were carried out in various in vitro cell models. The
limitations of these models are obvious, including differences in cellular milieu and receptor
expression levels. In this review, observations regarding in vivo trafficking of opioid receptors
will be presented. While some findings are consistent with in vitro results, others are
unanticipated.

Consideration of methods and approaches for subcellular localization of opioid receptors in
vivo
Each type of opioid receptor has a distinct distribution in the central nervous system as revealed
by receptor autoradiography studies (Mansour et al., 1988) and immunohistochemical
approaches (Arvidsson et al., 1995a, b). Some regions are abundantly enriched in opioid
receptors and these include the striatum, the locus coeruleus, the ventral tegmental area and the
dorsal horn of the spinal cords. Therefore, these regions are commonly used for studies on
endogenous opioid receptors.
The use of receptor autoradiography and electron microscopy was employed in the 1980s and
1990s (Moyse et al., 1997) where the opioid receptor ligands were labeled with 125I. The
localization of opioid receptors was detected using silver grains scattered by the radioactivity of
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the bound radioligands. Although a useful approach at the time, this technique fell out of favor
with the availability of specific antibodies that recognize each type of opioid receptors.
Immunohistochemistry combined with confocal microscopy is another useful approach.
Although confocal microscopes are more accessible than electron microscopes in most
laboratory settings, the resolution of the former is much lower than that provided by the latter.
Combining transmission electron microscopy with immunogold or immunoperoxidase labeling
provides a high-resolution technique for the study of the subcellular distribution of endogenous
opioid receptors in brain tissue. Although a more sensitive labeling approach, immunoperoxidase
labeling is not as readily quantifiable for subcellular distribution as the labeling tends to be
diffuse and has propensity to adsorb to membrane structures (Novikoff et al., 1972). In contrast,
immunogold labeling is quantifiable generally by counting the sliver grains. Therefore,
immunogold labeling is a major approach to quantify the subcellular localization of opioid
receptors.
Importantly, it can not be over-emphasized that, with all immunohistochemical approaches, the
validity of the results largely depends on the specificity and affinity of the antibodies. Specific
antibodies recognizing each type of opioid receptors are available and have been characterized
by different groups using complementary approaches.
Additional approaches have been used to investigate trafficking of epitope-tagged receptors
artificially introduced into animals. A mouse line expressing DOPR tagged with enhanced green
fluorescent protein (EGFP) at the C-terminus has been established using the gene targeting
approach and allows examination of whether there is a correlation between receptor trafficking
and in vivo pharmacology end points (Scherrer et al., 2006). Generation of such a knock-in
mouse line is time-consuming and costly.
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In another approach, exogenous opioid receptors, with epitope tags, have been introduced into
and expressed in certain brain regions by use of viral vectors (Haberstock-Debic et al., 2003).
Trafficking studies is carried out in a more physiological environment than in primary neurons.
This review does not cover the findings from such an approach.

Differential subcellular localization of endogenous opioid receptors
MOPR: Several lines of evidence indicate that, irrespective of the brain region, the MOPR is
mostly localized to plasma membranes (Fig. 1). For example, in the rat habenular nucleus,
confocal microscopy has shown that MOPR immunoreactivity is associated primarily with
plasma membranes of neurons (Keith et al., 1998). Using immunogold labeling combined with
electron microscopy, Van Bockstaele and Commons (2001) showed that about 90% of MOPR
immunoreactivity was located along the plasma membrane of somatodendritic processes in the
rat locus coeruleus . MOPR has been shown to have a similar subcellular distribution in the
striatal patches: 80% and 60% located on plasma membranes of dendritic spines and axon
terminals, respectively (Wang and Pickel, 2001). In the rat ventral tegmental area, immunogold
labeled MOPR was seen on plasma membranes of dendrites and axon terminals (Garzon and
Pickel, 2001). In the dorsal horn of rat spinal cord, most of the peroxidase-labeled MOPR was
associated with postsynaptic membranes of dendrites (Wang et al., 2003). Surprisingly, the
majority of immunogold-labeled MOPR (> 70%) was found in cytoplasm of the dendrites of C1
adrenergic neurons in the rat rostral ventrolateral medulla (Drake et al., 2005). It may reflect the
differential subcellular distribution of MOPR in brain regions.
DOPR: In contrast to the high percentage of MOPR associated with neuronal membranes,
DOPR immunolabeling is typically located intracellularly (Fig. 1). Electron microscopic analysis
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revealed that 80-90% of immunogold-labeled DOPR was found within the cytoplasm of rat
spinal cord dorsal horn dendrites (Cahill et al., 2001a, b). Further, this pattern is similar in
striatal patches (Wang and Pickel, 2001) where the prevalence of the intracellular distribution is
even more apparent in perikarya (Cahill et al., 2001a). In the ventral division of the reticular oral
pontine nucleus of the cat, the majority of DOPR immunoreactivity was located in the
cytoplasm of dendrites (79%), axons (81%) and somata (Alvira-Botero and Garzon, 2006). In the
rat and monkey dorsal root ganglia and dorsal horn, immunogold-labeled DOPR was frequently
associated with the membranes of large dense-core vesicles (Zhang et al., 1998).
In knock-in mice expressing DOPR-EGFP, quantitative analysis of confocal images indicates
that ~ 60% of DOPR-EGFP is present on the cell surface in the striatum (Scherrer et al., 2006).
It is noteworthy that the Bmax of [3H]naltrindole binding to DOPR in DOPR-EGFP knock-in mice
is twice as high as that in wild type mice. In addition, fusion of the DOPR at the C-terminus with
EGFP may affect interactions of the DOPR with associated proteins. These two factors may
affect expression, subcellular localization and trafficking of DOPR-EGFP.
KOPR: A number of neuroanatomical studies have shown that the KOPR is primarily
distributed intracellularly (Fig. 1), similar to the DOPR. Harris et al. (2004) reported that ~55%
of KOPR immuoreactivity was located intracellularly in the dendrites of rat spinal cords of both
sexes. In axon terminals, ~55% and 70% of KOPR immunoreactivity was intracellular in male
and female rats, respectively. We observed an even higher percentage (~70%) of KORP
immunoreactivity located intracellularly in the dendrites of male rat spinal cord (Wang et al.,
submitted). Most of intracellular KOPR was not associated with any discernable organelles, but
some immunoreactivity was associated with mitochondria and endosomes. In the rat posterior
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pituitary, ~60% of immunogold-labeled KOPR was associated with large secretory vesicles in
the axon terminals and only ~11% with plasma membranes (Shuster et al., 1999).
In contrast to its localization within dendrites, KOPR was frequently associated with small
synaptic vesicles in axon terminals of the rat nucleus accumbens (Svingos et al., 1999, 2001;
Meshul and McGinty, 2000). In addition, peroxidase-labeled KOPR immunoreactivity was
detected along plasma membranes of presynaptic axon terminals, large dense-core vesicles and
small vesicles of the hippocampus in guinea pigs (Drake et al., 1996). When interpreting these
results, one must take into consideration the known diffusion of peroxidase reaction products and
their possible absorption to membrane structures that may lead to an overestimation of the
association of KOPR immunoreactivity with plasma membranes and synaptic vesicle membranes.
Consistent with this notion is the finding that when KOPR was labeled with peroxidase it was
predominantly associated with plasma membranes of glial cells in rat medial prefrontal cortex,
but when labeled with immunogold, KOPR was mainly in the cytosol (Svingos and Colago,
2002).
In summary, in vivo experimental approaches have provided valuable insight into the differential
subcellular distributions of opioid receptors. The predominance of MOPR on the cell surface
and the greater prevalence of DOPR and KOPR intracellularly imply that the regulation of their
trafficking is likely to be different.

Trafficking of opioid receptors in vivo
The studies on trafficking of opioid receptors in vivo are summarized in Table 1.
MOPR: It was first demonstrated in cell models that MOPR agonists had differential effects on
internalization of the receptor. MOPR was internalized by acute treatment with enkephalins,
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etorphine or DAMGO, but not morphine (Arden et al., 1995; Keith et al., 1996). Agonistdependent internalization of MOPR has also been shown in tissues in vivo. Systemic injections
of etorphine caused rapid internalization of MOPR in neurons in the myenteric plexus of the
guinea pig as demonstrated by immunohistochemistry and confocal microscopy (Sternini et al.,
1996). In contrast, acute morphine treatment (30 min) did not change localization of MOPR.
Differential effects of etorphine and morphine on internalization of MOPR were also reported in
neurons of the rat brain using the same approach (Keith et al., 1998). By counting the MOPR
immunoreactive positive endosomes in confocal microscopy images, Trafton et al. (2000)
reported similar findings for MOPR in the dorsal horn of rat spinal cord, which was internalized
by DAMGO, remifentanil or endomorphin-1, but not morphine. Quantitative immunogold
electron microscopy showed that acute etorphine treatment (15 min) significantly reduced the
surface amount of MOPR in the dendrites in rat locus coeruleus (Fig. 1), whereas morphine,
either acute (30 min) or chronic (5 days), had no effect (Van Bockstaele and Commons, 2001).
In the dorsal horn of rat spinal cord, the endocytosed MOPR reappeared on cell surface within 60
min (Trafton et al., 2000). The magnitude of MOPR internalization in lamina II interneurons
induced by intrathecal DAMGO correlated with the extent of antinociception. However, such a
correlation did not exist in morphine-tolerant rats. Although the antinociceptive effect of
DAMGO was greatly decreased in morphine-tolerant rats, it promoted internalization of MOPR
to a similar extent as in control rats (Trafton and Basbaum, 2004), indicating the desensitized
MOPR retains the capability to be internalized. Surprisingly, although endogenous opioids are
expected to be released upon application of noxious stimuli, no MOPR internalization was
detected in lamina II neurons in nociception models, which may be due to inadequate amount of
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the released endogenous opioids (Trafton et al., 2000). The findings prompted the authors to
suggest that released opioid peptides may act presynaptically.
Although morphine alone did not induce significant internalization of MOPR, morphine plus
DAMGO, at a dose that did not cause endocytosis, internalized MOPR in the dorsal horns of rat
spinal cord as demonstrated in confocal images. The combination also reduced the development
of tolerance to chronic morphine treatment in rats (He et al., 2002). Recently, a knock-in mice
expressing mutated MOPR with DOPR C-tail has been established (Kim et al., 2008). The
mutant receptor in striatal neurons cultured from the knock-in mice were internalized by
morphine in vitro; however, it was not examined in vivo. The knock-in mice showed
significantly reduced tolerance and dependence to morphine (Kim et al., 2008). The authors
concluded that these findings supported the notion that tolerance to opioid receptors is due to
sustained activation of cell surface receptors.
Interestingly, trafficking of endogenous MOPR upon acute morphine treatment appears to be
compartment-specific. Haberstock-Debic et al. (2003) reported that in the rat nucleus accumbens,
morphine (30 min) translocated MOPR to intracellular sites in dendrites, but not in neuronal cell
bodies or axons. Drake et al. (2005) also observed that, in the rostral ventrolateral medulla,
morphine induced internalization of MOPR in dendrites that had diameters <1.4 µm, but not in
larger dendrites. These findings imply that the abundance of molecules involved in
internalization machinery may vary in different compartments of neurons. The impact from
surrounding environment or neural circuitries may also play a role.
Confocal microscopy images showed that the endogenous MOPR1C, a splice variant of MOPR,
in lateral septum was internalized by morphine administered intracerebroventricularly in mice
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(Abbadie and Pasternak, 2001), but MOPR was not. The difference in the C-terminal domains is
likely to account for their different abilities to be internalized.
Estrogen treatment also induced internalization of MOPR in medial preoptic nucleus and the
posteriodorsal medial amygdala of ovariectomized rats when using the increase of the density of
MOPR-immunoreactive fibers as an indicator for internalization (Eckersell et al., 1998). The
internalization was rapid (within 30 min) and long lasting (>24 hr). The mechanisms underlying
these observations are unknown.
DOPR: In DOPR-EGFP knock-in mice, acute treatment with SNC80 caused significant
internalization of DOPR in caudate putamen neurons in a dose-dependent manner, concomitant
with an increase in locomotor activity. In addition, DOPR internalization correlated with the
occurrence of desensitization to the subsequent application of SNC80 in enhancing locomotor
activity (Scherrer et al., 2006).
Since DOPR has a large intracellular pool, efforts were also devoted to investigating the stimuli
that can promote cell surface expression of DOPR. Chronic inflammatory pain up-regulated
mRNA and protein levels of DOPR in the dorsal horns of rat spinal cords, as demonstrated by in
situ hybridization and immunoblotting (Cahill et al., 2003). Immunoelectron microscopy studies
revealed that chronic inflammatory pain caused a significant increase of DOPR on the cell
surface and in peripheral zones under plasma membranes, which may account for the increased
antinociceptive efficacy of DOPR agonists in animals with chronic inflammatory pain (Cahill et
al., 2003).
Interestingly, chronic treatment with morphine promoted movement of intracellular DOPR to the
cell surface in the dorsal horn of rat spinal cord as shown by quantitative immunoelectron
microscopy (Fig. 1) (Cahill et al., 2001b). The effect of morphine was mediated by MOPR which
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was shown by using MOPR blockade and MOPR knock-out mice (Morinville et al., 2003).
Different from chronic inflammatory pain, morphine treatment regulated subcellular localization
of DOPR without affecting overall expression level of DOPR (Cahill et al., 2001b).
KOPR: Intrathecal injection of dynorphin A significantly decreased cell surface KOPR in the
dorsal horns of rat spinal cord, but U50,488H did not, using quantitative immunoelectron
microscopy (Wang et al., submitted). The differential effects of agonists may be due to the
distinct receptor conformations they induce. However, the in vivo effect of dynorphin A is more
complex. It has been reported that dynorphin A(2-17), the des-Tyr derivative of dynorphin A(117), can activate NMDA (Vanderah et al., 1996) or bradykinin (Lai et al., 2006) receptors at high
concentrations. It may also affect the trafficking of KOPR via neuronal circuitry.
KOPR in the posterior pituitary is mostly associated with vesicles containing vasopressin
(Shuster et al., 1999). When salt loading causes release of vasopressin, the KOPR is translocated
to cell surface along with fusion of secretory vesicles with plasma membranes (Fig. 1) (Shuster
et al., 1999).

Comparisons between in vivo and in vitro studies
MOPR: By and large, the results of the in vivo studies are similar to those of in vitro studies.
Most of the MOPR is present on cell membranes in transfected cells and in neurons in vivo.
DAMGO and etorphine cause significant internalization of MOPR, but morphine does not, both
in vitro and in vivo. However, the in vivo study revealed that morphine promoted redistribution
of endogenous MOPR in certain populations of dendrites. Its physiological significance is not
clear at the present time.

12

DOPR and KOPR: While DOPR and KOPR expressed in cells are mostly localized on cell
membranes, DOPR and KOPR in neuronal tissues in vivo are largely intracellularly located.
There are several possibilities for the differences. It may be due to differences in cellular milieu
between cell lines and neurons in the brain and spinal cord, including proteins involved in their
trafficking and interacting proteins. In addition, immunohistochemistry for KOPR and DOPR in
vitro was mostly performed with antibodies against an epitope tag added to the N-termini of the
receptors, whereas in vivo studies were conducted with DOPR and KOPR antibodies against Nor C-terminal domain of the receptors. Antibodies against different epitopes may not recognize
intracellular and cell surface receptors equally, thus producing different subcellular distribution
patterns. Indeed, Cahill et al. (2001a) reported that antibodies directed against a C-terminal
domain peptide of the DOPR recognized predominantly cell bodies and proximal dendrites,
whereas those directed against an N-terminal domain peptide, labeled extensively dendritic and
terminal arbors besides cell bodies. In addition, electron microscopy studies revealed that the two
antibodies label differentially with antibodies against the C-terminal peptide staining twice as
many DOPR-immunoreactivities on membranes compared to those against the N-terminal
peptide. Moreover, when the receptor was epitope-tagged with FLAG, in most cases it contained
a signal peptide to enhance endoplasmic reticulum membrane insertion and thus expression on
plasma membranes (Guan et al., 1992), which may contribute to the differences.
Since DOPR has a dramatic difference in localization between in vitro and in vivo, the in vivo
studies are focused on how intracellular DOPR is promoted to the cell surface, whereas the in
vitro investigations have been on agonist-induced internalization and trafficking of internalized
receptors.
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For the KOPR, the in vivo studies are consistent with several in vitro findings that U50,488H did
not internalize rat KOPR in cells (Li et al., 1999; Zhang et al., 2002).

Future studies
The in vivo studies have provided many descriptive observations. However, there is an obvious
lack of mechanistic studies.
Functional consequence of receptor trafficking in vivo: Scherrer et al. (2006) have
demonstrated in DOPR-EGFP mice that SNC80 enhances DOPR internalization in caudate
putamen neuron, which renders the animals less sensitive to the subsequent SNC80
administration (see above). In addition, Cahill et al. (2003) reported that inflammatory pain
promoted trafficking of DOPR to cell surface in dorsal horn of the rat spinal cord, leading to
enhanced response to DOPR agonists. More studies are needed to address the functional
significance of MOPR and KOPR trafficking in vivo. McLaughlin et al. (2004) found that
chronic U50,488H administration in mice enhanced KOPR phosphorylation and caused tolerance
to KOPR-mediated antinociception. Whether the tolerance is related to KOPR internalization
requires further study.

Mechanisms underlying the differential subcellular distribution of endogenous opioid
receptors: Although the three opioid receptors are highly homologous in their amino acid
sequences, in neuronal tissues MOPR is mostly on cell surface, whereas DOPR and KOPR are
predominantly intracellular. Since their sequences in the C-terminal domains are highly
divergent, it is tempting to speculate that the differences in this region result in their interactions
with different proteins, which play an important role in their subcellular localization. However,
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the majority of a mutated MOPR with the C-terminal domain replaced with that of the DOPR
was still found on cell surface in primary neurons cultured from the knock-in mice (Kim et al.,
2008). It will be interesting to directly examine the subcellular distribution of these mutant
receptors in vivo. Another possibility that can not be ruled out is that the differential distribution
may result from the differential recognition of the antibodies. Therefore, it is critical to further
characterize the subcellular localization of endogenous opioid receptors using antibodies against
different epitopes.
Drake et al.(2005) reported the majority of MOPR was located intracellularly in the dendrites of
C1 adrenergic neurons in the rat rostral ventrolateral medulla, in contrast to other brain regions.
Therefore, the differences in in vivo milieu, such as interacting proteins involved in trafficking,
may lead to their differential subcellular distribution in brain regions. Identification of the
interacting proteins that are involved in trafficking may help to elucidate the differences.
Constitutive internalization and recycling of endogenous opioid receptors may affect their
subcellular distribution. It has been reported that opioid receptors were differentially regulated in
the trafficking pathways in vitro. While internalized MOPR is mostly recycled, the majority of
endocytosed DOPR is sorted to lysosomes for degradation (von Zastrow et al., 2003).
Antagonists can be used to stop constitutive internalization and their effects on subcellular
localization of the receptors can be examined.
Most receptors in transfected cells appear to be on cell surface; therefore, the in vitro systems do
not always reflect the in vivo situations. One important task is to establish an in vitro system in
which subcellular distributions of opioid receptors mimic those in tissues. Kim and von Zastrow
(2003) found that treatment of PC12 cells with nerve growth factor caused cell differentiation
and retained the transfected DOPR intracellularly; whereas transfected MOPR is mostly on cell
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surface. This may be a good in vitro system that allows studies on mechanisms underlying
differential subcellular distribution.
Mechanisms underlying the compartment-selective internalization of MOPR by morphine:
MOPR is internalized by morphine treatment in vitro when G protein-coupled receptor kinase 2
is over-expressed (Zhang et al., 1998). It is possible that different compartments of neurons may
have distinct compositions and/or abundance of internalization machinery components. In
addition, we have reported previously that MOPR displayed differential glycosylation in
different brain regions (Huang et al., 2008). Thus, it will be interesting to examine if the MOPR
in different neuronal compartment may have distinct post-translational modifications.
Mechanisms underlying the promotion of intracellular DOPR to the cell surface: Morphine
treatment enhances cell surface level of endogenous DOPR and the MOPR is required for this
action. Mechanisms for this process are not clear. MOPR and DOPR have been demonstrated to
form dimers in vitro (George et al., 2000; Gomes et al., 2000); however, there is no definitive
evidence showing their in vivo dimerization. It will be interesting to study if MOPR-DOPR
dimerization is involved. Unfortunately, there are no reagents that can promote or block
dimerization of MOPR-DOPR. Alternatively, morphine may act on the MOPR via neuronal
circuitry and ultimately leads to enhancement in cell surface expression of the DOPR. If this is
the case, the neuronal circuitry needs to be identified.
Chronic inflammation also enhances cell surface DOPR. Biochemical processes leading to the
enhancement remains to be determined. It is likely that chemical mediators of inflammation and
subsequent activation of their receptors and down-stream effectors may be involved.
Functional significance of intracellular pool of KOPR: KOPR has a large intracellular pool in
dorsal horns of the rat spinal cord, which was mostly dispersed in the cytosol without association
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with any organelles. It will be interesting to investigate whether the intracellular KOPR can be
translocated to cell surface under certain physiological or pathophysiological conditions.
Infusion of U69,593, a selective KOPR agonist, to rostral ventromedial medulla produced
antinociceptive effects against chemical or mechanical stimuli (Schepers et al., 2007). The
efficacy of U69,593 was significantly enhanced in animals that had chronic inflammatory pain
induced by hind paw injection of complete Freund's adjuvant. The presence of KOPR in rostral
ventromedial medulla has been reported (Drake et al., 2007). Whether the enhanced efficacy of
U69,593 is due to the increase in the number of cell surface KOPR and/or down-stream signaling
needs further investigation.
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Figure Legend
Fig. 1 Illustration of electron microscopy findings on subcellular distribution of
endogenous opioid receptors and their trafficking upon stimulation in vivo.
Upper panel, MOPR is predominantly present on cell surface. MOPR is internalized following
treatment with etorphine or DAMGO, but not morphine, in spinal cord, myenteric plexus and
several brain regions. Morphine causes internalization of MOPR in the dendrites, but not in the
cell body, in the nucleus accumbens.
Middle panel, DOPR is mostly intracellular. Pretreatment with morphine or chronic
inflammatory pain enhances trafficking of intracellular DOPR to cell surface in the spinal cord.
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Lower panel, KOPR has a significant intracellular pool. In the posterior pituitary, salt loading
promotes the insertion of KOPR on vasopressin-containing vesicles into cell surface of axon
terminals.
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Table 1. Summarization of in vivo trafficking of endogenous opioid receptors
Receptor
MOPR

Method
immunohistochemi
stry + confocal
microscopy

immunogoldlabeling +
electronmicroscopy

DOPR

KOPR

Animal
guinea pig

Region
myenteric plexus

Stimulation
acute etorphine or
morphine

rat

dorsal horn of
spinal cord

DAMGO,
remifentanil,
endomorphin-1 or
morphine; noxious
stimuli

morphine
tolerant rat

dorsal horn of
spinal cord

DAMGO

rat

dorsal horn of
spinal cord

rat

Lateral septum

DAMGO (low
dose that did not
promote
internalization) +
Morphine
acute morphine

OVX rat

medial preoptic
nucleus;
posterodorsal
medial amygdale
locus coeruleus

rat

confocal
microscopy

knock-in
mouse

immunogoldlabeling + electron
microscopy

rat

immunogoldlabeling + electron
microscopy

rat

Findings
internalized by
etorphine, but not
by morphine
internalized by
DAMGO,
remifentanil,
endomorphin-1, but
not by morphine or
noxious stimuli
DAMGO caused
similar magnitudes
of internalization in
control and tolerant
rats
Promoted
internalization

Reference
(Sternini et
al., 1996)

MOPR1C
internalized

(Abbadie
and
Pasternak,
2001)
(Eckersell et
al., 1998)

estrogen

internalization

acute etorphine or
morphine

internalized by
etorphine, but not
by morphine

nucleus
accumbens

acute morphine

rostral
ventrolateral
medulla
striatum

acute morphine

dorsal horn of
spinal cord

Chronic
inflammatory pain

dorsal horn of
spinal cord
hypothalamus

Chronic morphine
treatment
U50,488H or
dynorphin A
salt loading

internalized in
dendrites, but not in
cell bodies
internalized only in
the dendrites with
diameter <1.4 µm
internalization
correlated with
tolerance
up-regulation and
translocation to
surface
translocation to
surface
internalized by
dynorphin A
inserted into cell
surface

SNC80

(Trafton et
al., 2000)

(Trafton and
Basbaum,
2004)

(He et al.,
2002)

(Van
Bockstaele
and
Commons,
2001)
(Haberstock
-Debic et
al., 2003)
(Drake et
al., 2005)
(Scherrer et
al., 2006)
(Cahill et
al., 2003)
(Cahill et
al.,2001b)
(Wang et al.
submitted)
(Shuster et
al., 1999)
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